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Abstract 
Background: Human immunodeficiency virus (HIV) is one of the major infectious agents, which has important 
role in the public health challenges, which have affected the world's economic and social situation recent 
decades. During the last decades, millions of people died due to HIV infection worldwide. However, data 
remain limited on the causes of death among HIV-infected in Iranian population. The aim of the present study 
was to assess the cause specific death among HIV positive inpatient persons in Iran. 
Materials and Methods: This surveillance was conducted on inpatient HIV positive admissions at Masih 
Daneshvari Hospital, Tehran, Iran during October 2016 and April 2017.All patient’s data were collected via 
abstraction form, which were ascertained, from medical records and from written logbooks that were kept by 
the nursing staff on the ward. The data of each admission was recorded from the medical reports at the time of 
admission and upon discharge. All laboratory data were collected and recorded separately. 
Results: Fifty persons were diagnosed as HIV-infected patients, of which 58% of them were classified as 
AIDS patients. Our findings indicated that the cause of hospitalization were pulmonary 54%, neurological 
20%, gastrointestinal 16%, and dermal 10% complications. Overall, 21 patients (42%) were diagnosed with 
pulmonary tuberculosis, of which one patient died from tuberculosis complications. Four patients died during 
the study period. 
Conclusion: In conclusion, early treatment and/or early use of ART can be improved outcomes. Therefore, 
early HIV testing and early ART use play important role in mortality reduction among eligible persons. 
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Introduction 
Up-to-date and comprehensive data and evidence for 
levels and trends is critical for informed priority 
setting for each country. Trends quantify progress 
against explicit health targets, whether local, 
national, or global, and help to evaluate where 
programs are working or not. To identify emerging 
public health challenges, regular comprehensive 
updates about causes of death seems to be crucial1.  
According to the health setting reports, morbidity and 
mortality remain high among HIV-infected patients3-5. 
The mortality rates may differ by the rate of uptake 
appropriate treatment and by the available level of care 
at each facility6. Since 1996, by using combination, 
antiretroviral treatment (ART) the prognosis of HIV-
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positive patients was consistently improving and the 
HIV-related morbidity and mortality rates have been 
decreased worldwide7-10. However, it remains limited 
data evaluating mortality by HIV status among 
inpatient facilities in Iran. Nevertheless, the case 
management of HIV-positive patients remains 
challenging in our country, because there are some 
problems. In this regard, late diagnosis of HIV 
infection and late initiation of treatment lead to 
increasing of AIDS-related morbidity rate among 
population8,11-14. Following the AIDS-related 
morbidity, tuberculosis (TB) and invasive bacterial 
diseases are the most frequent disorders in these 
patients11,12,15,16. In other hand, treatment byART 
regimens may has some adverse effects, and even 
HIV-positive patients may experience a wider range 
of co-morbidities, including cancers and 
cardiovascular diseases17,18.  
It has been reported that, widespread use of highly 
active antiretroviral therapy (HAART) can lead to 
changing of causes of death among HIV positive 
patients dramatically19-24.Thus, examining the 
changes in causes of death can inform the clinical 
management of HIV-infected persons in each 
geographical situation and also surveying mortality 
in HIV-infected population is more useful for 
detecting variation in the availability, utilization, 
timeliness, or quality of care for this population. 
Therefore, the aim of the present study was to assess 
the cause specific death among HIV positive inpatient 
persons in Masih Daneshvari Hospital, Tehran, Iran. 
Methods 
The present study was conducted as a cross sectional 
surveillance of inpatient HIV positive admissions at 
Masih Daneshvari hospital, Tehran (capital city of 
Iran), Iran. All medical admissions from medical 
wards were recorded over a six-month period between 
October 2016 and April 2017. Masih Daneshvari 
hospital with 350 beds is affiliated to Shahid Beheshti 
University of Medical Sciences, Tehran, Iran. This 
hospital selected by the World Health Organization 
(WHO) as the center for educating students in 
tuberculosis in the Eastern Mediterranean region 
(EMRO) at the national level. The Ethics Committee 
of School of Medicine, Shahid Beheshti University of 
Medical Sciences approved this study 
(IR.SBMU.MSP.REC.1395.369). In this study, 
individual informed consent from the participants were 
obtained before enrollment. 
All patient’s data were collected via abstraction form, 
Table 1: Laboratory characteristics of HIV-infected patients attended at Masih Daneshvari Hospital, Tehran, Iran, 
between 2004 and 2014. 
Characteristics Live patients (n=46) Died persons (n=4) 
Viral load   
>50 copies/ml 17.4% (n=8) 50% (n=2) 
50-499 copies/ml 10.9% (n=5) 25% (n=1) 
500-29999 copies/ml 30.4% (n=14) 25% (n=1) 
≥30000 copies/ml 41.3% (n=19) 0% (n=0) 
CD4 count    
≥500 cells/microL 17.4% (n=8) 0% (n=0) 
200-499 cells/microL 28.3% (n=13) 50% (n=2) 
<200 cells/microL 54.3% (n=25) 50% (n=2) 
HBS-Ag   
Positive  4.3% (n=2) 0% (n=0) 
Negative 95.7% (n=44) 100% (n=4) 
Anti-HCV-antibody    
Positive  32.6% (n=15) 0% (n=0) 
Negative 67.4% (n=31) 100% (n=4) 
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which were ascertained, from medical records and 
from written logbooks that were kept by the nursing 
staff on the ward. The data of each admission was 
recorded from the medical reports at the time of 
admission and upon discharge. All laboratory data 
were collected and recorded separately. The collected 
data consist of patient demographics, HIV testing, 
HIV status, CD4 cell count, ART status and current 
viral and immunological markers, hematological 
tests, biochemical tests, microbiological tests, 
admission diagnosis, and discharge diagnosis. The 
outcome of each patients was recorded as 
‘discharged’, ‘died’, or ‘transferred to another 
hospital’.  
All data were entered into a SPSS statistical software 
version 22.0 (IBM Corp., Armonk, USA). Fisher’s 
exact test and Chi Square test were used for assessing 
the significant correlation between variables. For 
analyzing the ‘died’ and ‘alive’ groups, Mann-
Whitney U test was used. For all tests and analysis, 
the 5% level was considered statistically significant. 
Results 
In the present study, from 487 persons suspected 
with HIV infection, 50 were diagnosed as HIV-
infected patients, of which 58% (n=29) of them were 
classified as AIDS patients. The patient’s age range 
was from 20 to 72 years old. The median age of the 
patients was 34±3 years. A total of 78% (n: 39) of the 
HIV-infected patients were male and 22% (n: 11) 
were female, of which 54% were married, 40% (n: 
20) were single and 6% (n: 3) were divorce cases. 
Our analysis indicated that 52% (n: 26) of the 
patients were unemployment. Four patients died 
during the study period; in which Tuberculosis, brain 
abscess, edema and stroke were identified as causes 
of death. Table/Fig 1 shows the laboratory 
characteristics and co-infection with hepatitis virus 
among the HIV-infected patients in this study.  
Our results indicated that 42% (n: 21) of the HIV-
positive patients were considered as having high-risk 
perceptions about HIV infection through a self-report 
questionnaire and met the inclusion criteria. The 
frequency of these risk factors has been indicated in 
Table 2. Our findings indicated that the cause of 
hospitalization were pulmonary 54% (n: 27), 
neurological 20% (n: 10), gastrointestinal 16% (n: 8), 
and dermal 10% (n: 5) complications. Overall, 21 
patients (42%) were diagnosed with pulmonary 
tuberculosis, of which one patient died from 
tuberculosis complications. Table 3 illustrates the 
frequency of clinical manifestationsamong the HIV-
positive patients. 
Discussion 
In present study, causes of death of hospitalized HIV-
positive patients were studied and were compare with 
different variables. According to our analysis, age, 
male gender and low number of CD4 cells (CD4< 
200) are associated with increasing the mortality in 
HIV positive patients (pV< 0.05). Perry et al, were 
conducted a study in Africa. They showed, among 
HIV-positive patients who died, a low CD4 cell count 
(<200) was associated with death and they reported 
that, patients who died had significantly more 
neurological and respiratory-related presenting 
Table 2: Demographic and HIV-risk history 
characteristics of HIV- infected patients in attended 
at Masih Daneshvari Hospital, Tehran, Iran, between 
2004 and 2014. 
Characteristics  Percentage (number) 
Marital status  
Married  54% (n=27) 
Single  40% (n=20) 
Divorced  6% (n=3) 
Education  
Illiterate 22% (n=11) 
Less than high school 48% (n=24) 
High school diploma 28% (n=14) 
College education 2% (n=1) 
Sexual orientation  
Heterosexual (male) 26% (n=13) 
Heterosexual (female) 16% (n=8) 
Homosexual or gay 4% (n=2) 
Unclear  54%  (n=27) 
Intravenous drug user  
Male  32%  (n=16) 
Female  6%  (n=3) 
Cupping history 14% (n=7) 
Tattoo history 34% (n=17) 
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complaints than patients did who survived6. Our 
study showed, mortality rate among HIV positive 
inpatients was 8%, which very lower than mortality 
rate in Africa, which reported 23%6. In addition, in 
present study, Tuberculosis, brain abscess, edema 
and stroke were identified as causes of death. It has 
been reported that, mortality rates increased of HIV 
positive inpatients in Zimbabwe was from 13.3 to 
28.6% between 1992 and 200224-26. Although overall 
mortality in present study was lower than some 
settings, controlling and preventing to death among 
the HIV-positive patients is concerning. 
Our result showed, 42% of HIV positive patients 
were infected by Mycobacterium tuberculosis 
(MTB). According to Jam et al study in 2010, 24% of 
HIV positive patients in Tehran HIV centers were 
infected by MTB [27]. Later, Khosravi et al during 
2012 in Ahvaz province, southwest of Iran, has been 
reported that, 23% of HIV positive patients suffered 
by MTB28. It seems that, MTB morbidity was 
increasing among HIV positive persons. Importantly, 
tuberculosis is endemic in our country, and 
unfortunately, the rate of resistant strains is 
increasing29,30. 
According to our analysis, 30% of HIV positive 
patients were infected by HCV. The importance of 
HCV/HIV coinfection on overall and cause-specific 
mortality was discussed31-33. However, according to 
Table 3: The frequency of different clinical manifestationsamong the HIV-positive patients. 




Alveolar 4.3% (n=2) 0% (n=0) 
Cavitary 26.1% (n=12) 0% (n=0) 
Interstitial 8.7% (n=4) 0% (n=0) 
Reticular 4.3% (n=2) 0% (n=0) 
Nodular 23.9% (n=11) 25% (n=1) 
Normal 32.6% (n=15) 75% (n=3) 
Cerebral complications     
Mass lesion 6.5% (n=3) 75% (n=3) 
Edema  2.2% (n=1) 25% (n=1) 
Atrophy 4.3% (n=2) 0% (n=0) 
Normal  87% (n=40) 0% (n=0) 
Gastrointestinal complications     
Liver disorder   8.7% (n=4) 0% (n=0) 
Esophageal complication 6.5% (n=3) 0% (n=0) 
Peritoneum complication  2.2% (n=1) 0% (n=0) 
Colon complication  2.2% (n=1) 0% (n=0) 
Normal  80.4% (n=37) 100% (n=4) 
Dermal disorders   
Plaque   6.5% (n=3) 0% (n=0) 
Ulcer  4.3% (n=2) 0% (n=0) 
Abscess  4.3% (n=2) 0% (n=0) 
Normal  87% (n=40) 100% (n=4) 
Tuberculosis  43.5% (n=20) 25% (n=1) 
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literature, the role of HCV coinfection in mortality 
associated with HIV is unclear yet. Some studies 
have showed HCV infection does not accelerate CD4 
decline and AIDS progression34,35. Other reports 
suggested that HCV coinfection is increasing risk for 
progression to AIDS36. It has been reported that37 
eradication of HCV in HIV/HCV positive patients is 
accompanying with decreases lower risks of both 
liver and non-liver-related mortality and HIV 
progression. In present study, the count of CD4 cells 
in HIV/HCV positive patients was <200 
cells/microL. 
Conclusion 
In conclusion, early treatment and/or early use of 
ART can be improved outcomes. It proven that lower 
CD4 cell count is associated with increased 
mortality, therefore early HIV testing and early ART 
use play important role in mortality reduction among 
eligible persons. In addition, bacterial infections were 
also frequent causes of hospitalization among HIV 
positive persons. Among these infections, TB is the 
major cause of hospitalization of HIV-positive 
persons worldwide. Prophylaxis and controlling 
programs should be update and new ways, strategies 
and antibacterial agents should be designed for 
treatment of drug resistant strains. 
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